Piper Sandler initiated coverage of GeneDx (WGS) with an Overweight rating and $110 price target The firm views the company as a “fast grower in the under-penetrated” rare disease testing market. GeneDx has a “unique first-mover advantage” in rare disease testing and is at the beginning of profitability, the analyst tells investors in a research note. Piper sees a compelling entry point at current share levels.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx price target raised to $115 from $88 at Guggenheim
- GeneDx announces SeqFirst study data on rapid genomic testing in pediatrics
- GeneDx says AAP recommends exome, genome sequencing as tests for children
- AAP guidance ‘another reason to believe’ in GeneDx, says Craig-Hallum
- GeneDx Holdings: Navigating Market Opportunities and Delayed Financial Impact Amid AAP Testing Guidelines Update